This is to inform that due to some circumstances beyond the organizer control, “2nd Edition of International Conference on Gastroenterology” (Gastro 2024) during October 21-23, 2024 at Baltimore, MD, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at gastroenterology@magnusconference.com or call + 1 (702) 988-2320.
Evidence-based medicine (EBM) is an approach to healthcare that is based on the best available scientific evidence in order to make decisions about diagnosis, treatment and prevention. This approach is increasingly being used to treat gastrointestinal (GI) disorders such as irritable bowel syndrome (IBS), Crohn's disease and ulcerative colitis. EBM helps healthcare professionals to identify the most effective treatments for GI disorders and make them available to patients. It also helps healthcare providers to identify and address gaps in care and make sure that patients receive evidence-based treatments. A key element of EBM is the use of clinical practice guidelines, which are based on the latest scientific evidence and provide recommendations for the diagnosis and treatment of GI disorders. EBM also emphasizes the importance of patient-centered care, which means that healthcare professionals should take into account patient preferences and values when making decisions about diagnosis and treatment. In addition, EBM encourages the use of shared decision-making between healthcare professionals and patients, which allows both parties to be involved in the decision-making process. EBM has been found to be effective in the treatment of GI disorders, as it has been shown to improve patient outcomes and reduce healthcare costs. For example, a systematic review of studies on EBM for GI disorders found that EBM interventions resulted in better outcomes for patients with IBS. In addition, studies have found that EBM interventions can reduce costs associated with GI disorders, such as the costs of medications and hospitalizations. Overall, EBM is an important approach to healthcare that has been shown to be effective in the treatment of GI disorders. By using the best available scientific evidence, healthcare professionals can provide evidence-based treatments to their patients and ensure that they receive the best possible care.
Title : Novel exosomal biomarkers for MASH
Aleksandra Leszczynska, University of California San Diego, United States
Title : Validation of GLAS (GP73+LG2m+Age+Sex) and ASAP (Age+Sex+AFP+PIVKA-II) algorithms for the management of liver fibrosis, cirrhosis and cancer
Philip M Hemken, Abbott Diagnostics Division R&D, United States
Title : Reverse multiple myeloma: First hepatic amyloidosis then multiple myeloma
Milaris M Sanchez Cordero, Mayaguez Medical Center, Puerto Rico
Title : Autophagy promotes the survival of adipose mesenchymal stem/stromal cells and enhances their therapeutic effects in cisplatin-induced liver injury via modulating TGF-1/Smad and PI3K/AKT signaling pathways
Eman Mohamad EL Nashar, King Khalid University, Saudi Arabia
Title : Epigastric Impedance measures gastric malfunction non-invasively. Time to revive it
John Andrew Sutton, Gastria Ltd, United Kingdom
Title : Digesting the connection: Exploring the psychological impact of gastroenterology issues on mental and emotional well being
Tracy E Hill, MGS Products LLC, United States